Development of the PANVAC-VF vaccine for pancreatic cancer (Q36383786)

13 August 2017

1 reference

title

Development of the PANVAC-VF vaccine for pancreatic cancer (English)

1 reference

13 August 2017

1 reference

Christian A Petrulio

1

1 reference

13 August 2017

Howard L Kaufman

series ordinal

2

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Expert Review of Vaccines

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

9-19

1 reference

Edward Jenner's Inquiry; a bicentenary analysis

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

An update on the vaccinia virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Preventing the return of smallpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Poxviruses as expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Vaccinia virus vectors for gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Poxvirus vaccines for cancer and HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Coley's toxins in perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Animal models of tumor immunity, immunotherapy and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Update on cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Immunotherapy for pancreatic cancer: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

MUC1 and the immunobiology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

The biochemistry and cell biology of antigen processing and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

The expanding world of co-stimulation: the two-signal model revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Boosting T cell costimulation in cancer: the possibilities seem endless

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Vaccines with enhanced costimulation maintain high avidity memory CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

Pancreatic cancer: a review of emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.9

21 January 2018

Identifiers

DOI

10.1586/14760584.5.1.9

1 reference

13 August 2017

1 reference